Advertisement

Picture BCNP Consultants European Chemistry Partnering 2018 Ffm Germany 600x60px
Document › Details

Biodesix, Inc.. (3/20/17). "Press Release: Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber. Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients".

Region Region Praha (Prague)
  Country Czech Republic
Organisation Organisation Biodesix Inc.
Products Product clinical proteomic test
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
     


Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in immuno-oncology. These blood-based tests, which were developed on Biodesix’s proprietary Diagnostic Cortex™ platform, may identify patients who derive significant benefit from anti-PD-1 monotherapy and might not gain additional benefit from the addition of anti-CTLA-4 agents. Dr. Weber will make his presentation at the 4th Immunotherapy of Cancer Conference in Europe (ITOC4).

Session Title: Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients
Plenary Session Date/Time: Tuesday March 21, 4:50PM
Location: Prague Congress Center, 5 Kvetna 65, Prague, Czech Republic


About Jeffery Weber

Jeffrey S. Weber, MD, Ph.D, is the deputy director of the Perlmutter Cancer Center at New York University – Langone Medical Center, where he serves as a Professor in the Department of Medicine. Dr. Weber is co-director of the Center’s Melanoma Research Program.


About Biodesix

Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix designs, develops and commercializes multivariate molecular liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with real-time clinical data at diagnosis with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel clinical tests independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.

   
Record changed: 2017-03-22

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Biodesix Inc.


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px